Dynamics of onychodystrophy manifestations in patients with torpid psoriasis treated with an interleukin-17 blocker
Khotko A.A., Inyukhina E.A., Kozyr Ya.V.
Background: Psoriasis in children, especially with nail plate involvement and juvenile psoriatic arthritis, is a complex clinical problem for which there is a lack of data on the safety and efficacy of newer systemic therapies. Therefore, it is necessary to present clinical observations using modern medications.
Description of the clinical cases: Two clinical observations of children aged 12 and 11 years with progressive vulgar psoriasis complicated by nail involvement are presented. One patient was diagnosed with juvenile psoriatic arthritis. In both cases, traditional treatment approaches (topical agents, phototherapy, methotrexate) were insufficiently effective or were associated with adverse effects. Use of secukinumab according to approved treatment regimens resulted in significant clinical remission of skin and nail lesions by weeks 16–24, with a reduction in PASI scores to 0 and NAPSI to 0, as well as an improvement in quality of life and the absence of serious adverse effects. Pre-therapy assessments included serological and radiographic tests, as well as consultations with specialized specialists to confirm the absence of contraindications.
Conclusion: These clinical cases demonstrate the high efficacy and safety of secukinumab in children with severe psoriasis and nail lesions. This confirms the feasibility of using this biologic agent in pediatric patients who have failed traditional treatments and who need to improve their quality of life.
For citations: Khotko A.A., Inyukhina E.A., Kozyr Ya.V. Dynamics of onychodystrophy manifestations in patients with torpid psoriasis treated with an interleukin-17 blocker. Pharmateca. 2025;32(10):137-142. (In Russ.). DOI: https://dx.doi.org/10.18565/pharmateca.2025.10.137-142
Authors’ contribution: A.A. Khotko – study concept and design, data analysis and interpretation, editing and approval of the final version of the article. E.A. Inyukhina – clinical data collection and analysis, manuscript preparation and formatting, article editing. Ya.V. Kozyr – clinical data collection, data analysis, preparation of illustrations, participation in text editing.
Conflicts of interest: The authors confirm that they have no conflicts of interest to declare.
Funding: The study was conducted without any sponsorship.
Patient Consent for Publication: Patients/patients’ legal representatives signed informed consent for the publication of their data.
Keywords
nail psoriasis
childhood psoriasis
biological therapy
secukinumab
About the Authors
A.A. Khotko, Dr. Sci. (Med.), Dermatovenereologist, Deputy Chief Physician for Medical Affairs, Clinical Dermatovenereology Dispensary (Krasnodar); Associate Professor, Department of Dermatovenereology and Cosmetology, Central State Medical Academy of the Administrative Directorate of the President of the Russian Federation, Moscow, Russia; ORCID: https://orcid.org/0000-0002-8688-4876E.A. Inyukhina, Dermatovenereologist, Head of Dermatology Department No. 1, Clinical Dermatovenereology Dispensary, Krasnodar, Russia; chernenko_ea@mail.ru, ORCID: https://orcid.org/0000-0003-0919-1184, SPIN: 7616-5864 (corresponding author)
Ya.V. Kozyr, Dermatovenerologist, Department of Paid Medical Services, Clinical Dermatovenereology Dispensary, Krasnodar, Russia; ORCID: https://orcid.org/0000-0001-9880-0417
Similar Articles
